Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients

Phase 1

Completed

• Conditions: Relapsed/Refractory AML
• Interventions: Drug: Uproleselan

• Registration Number: NCT04839341
• Lead Sponsor: Apollomics Inc.

Brief Summary

This study will evaluate the safety and tolerability of uproleselan(GMI-1271), a specific E-selectin antagonist, and characterize the pharmacokinetic (PK) profile of uproleselan, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients.

Detailed Description

This study is a multicenter open-labelled study conducted in subjects with relapsed or refractory AML in China. The study includes the following phases: screening phase, induction phase, consolidation phase baseline, consolidation phase and follow-up period.

Screening phase:

This study will enroll 12 subjects, who are 18 to 60 years (inclusive) at the time of signing the Informed Consent Form (ICF), and with the diagnosis as relapsed or refractory AML. Screening is conducted 21 days to 2 days before administration, and signed ICF by the subject must be obtained before screening.

Baseline period:

The baseline period is 1 day before study drug administration.

Induction treatment:

During the induction phase, subjects will receive 8 consecutive days of uproleselan treatment and 5 consecutive days of MEC (mitoxantrone, etoposide, and cytarabine combined regimen) chemotherapy.

Consolidation baseline:

The baseline of the consolidation phase is 1 day before the treatment administration of the consolidation phase.

Consolidation treatment:

Subjects who met the criteria for consolidation treatment started the consolidation period at the 29th day of the previous treatment cycle at the earliest and the 65th day at the latest.

Follow-up period:

Each subject should complete the following follow-up stage: (1) Response evaluation to determine remission to the induction treatment (induction period); (2) EOT assessment after completing the last consolidation treatment cycle; (3) Death. Survival and long-term follow-up, including initiation of new anti-leukemia treatment (within 6 months after the last uproleselan/placebo administration), recurrence, HSCT and survival events, monthly (±14 days) for 2 years after the end of treatment, and afterwards quarterly (±14 days). The longest survival follow-up time is 3 years (calculated from the start of treatment).

Study Timeline

• Study Start: 2021-02-24
• Study First Submitted: 2021-03-22
• Study First Submitted QC: 2021-04-07
• Study First Posted: 2021-04-09
• Primary Completion: 2024-06-28
• Study Completion: 2024-06-28
• Status Verified: 2025-06
• Last Update Submitted: 2025-06-24
• Last Update Posted: 2025-06-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

1. ≥18 years and ≤60 years in age

2. AML (including secondary AML) diagnosed as per WHO standards (2008).

3. For refractory AML, only cytarabine/daunorubicin(or Idarubicin) as can be applied repeatedly(maximal twice) as induction, no other chemotherapy are allowed to be applied Venatoclax /hypomethylation drug [HMA] can be used before and after chemotherapy.

   1. For relapse AML, it must be the first or second relapse, and remain untreated.
   2. Certain regimens (Venatoclax/HMA, Venetoclax/LDAC, HMA single agent) and FLT3 inhibitors, tyrosine kinase inhibitors, IDH1/IDH2 inhibitors or similar targeted inhibitors used alone are not considered cytotoxic chemotherapy are allowed.

4. ECOG performance status score is 0 to 2.

5. Stable hemodynamics and good organ function.

Exclusion Criteria

1. Patients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or secondary refractory AML.
2. Active signs or symptoms of CNS involvement by malignancy.
3. Stem cell transplantation ≤4 months prior to dosing.
4. Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing.
5. Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.
6. Inadequate organ function.
7. Abnormal liver function.
8. Known active infection with hepatitis A, B, or C, or human immunodeficiency virus.
9. Moderate kidney dysfunction (glomerular filtration rate <45 mL/min).
10. Uncontrolled acute life-threatening bacterial, viral, or fungal infection.
11. Clinically significant cardiovascular disease.
12. Major surgery within 4 weeks of dosing.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
A Phase I, open-labeled multicenter study	Uproleselan	Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC)

Primary Outcome Measures

Name	Time	Method
Peak plasma concentration (Tmax)	14 days	To assess the pharmacokinetic profile in patients with relapsed/refractory AML.
Peak plasma concentration (Cmax)	14 days	To assess the pharmacokinetic profile in patients with relapsed/refractory AML.
Area under the plasma concentration-time curve from time zero to 12 hours (AUC0-12)	14 days	To assess the pharmacokinetic profile in patients with relapsed/refractory AML.
The area under the plasma concentration-time curve (AUC0-t) from time zero to the last measurable time point	14 days	To assess the pharmacokinetic profile in patients with relapsed/refractory AML.
The Incidence of Adverse Events	Up to 10 months	Number of participants with an AE.
The tolerance of participants with relapsed/refractory AML.	Up to 10 months	Number of participants could tolerate the Uproleselan combined with chemotherapy.

Secondary Outcome Measures

Name	Time	Method
OS	Up to 3 years	Defined as the period from when the subject receives the first dose of the study drug to death from any cause;
Remission rate (rate of CR, CR/CRi and CR/CRh)	Up to 60 days	Defined as the rate of subjects who reach CR, CR/CRi and CR/CRh;
CTCAE grade 3 and 4 oral mucositis	Up to 254 days	The incidence of CTCAE grade 3 and 4 oral mucositis during the treatment duration.

Trial Locations

Locations (2)

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; 🇨🇳 Tianjin, Tianjin, China

The First Affiliated Hospital of Zhejiang University; 🇨🇳 Hangzhou, China